G. Dueck

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

J. Gribben, G. Salles, L. Sehn, 2016, The Lancet. Oncology.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J. Gribben, G. Salles, L. Sehn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma

T. Reiman, A. Belch, J. Johnston, 2015, Cancer.

Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma

T. Reiman, A. Belch, J. Johnston, 2010, Cancer.

Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.

L. Sehn, H. Bruyèrè, P. Tsang, 2021, Leukemia research.

Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases.

T. Reiman, A. Belch, J. Johnston, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.

L. Sehn, H. Bruyèrè, P. Tsang, 2020, Leukemia research.

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

T. Reiman, Sunita Ghosh, L. Pilarski, 2011, Leukemia research.

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

J. Gribben, G. Salles, L. Sehn, 2016 .

Genetic relations and phylogeography of woodland and barrenground caribou

G. Dueck, 1998 .

GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

J. Gribben, G. Salles, B. Cheson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.